Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
24 Aortic Stenosis Trials near Chicago, IL
Power is an online platform that helps thousands of Aortic Stenosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerSAPIEN X4 THV for Aortic Stenosis
Evanston, IllinoisThis trial is testing a new heart valve that can be inserted without surgery in patients with severe heart valve narrowing. The new valve helps improve blood flow by replacing the damaged one through a minimally invasive procedure.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
915 Participants Needed
Aortic Valve-in-Valve for Aortic Stenosis
Chicago, IllinoisThis study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:All
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Regurgitation, Myocardial Infarction, Stroke, Others
125 Participants Needed
SAPIEN 3 THV for Aortic Stenosis
Chicago, IllinoisTo establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in patients with severe, calcific aortic stenosis who are at low operative risk for standard aortic valve replacement.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
1000 Participants Needed
TAVR for Aortic Stenosis
Chicago, IllinoisThe purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, and severe aortic stenosis, and those with intermediate risk.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:19+
Sex:All
1074 Participants Needed
TAVR for Aortic Stenosis
Chicago, IllinoisThis study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
901 Participants Needed
TAVR for Aortic Stenosis
Chicago, IllinoisThis trial tests advanced heart valves that can be inserted without open-heart surgery in patients with a narrowed and stiff aortic valve due to calcium buildup. The new valve is placed through a small cut and guided to the heart, where it replaces the damaged valve. This minimally invasive procedure has recently become the only lifesaving solution for patients who cannot tolerate standard surgical valve replacement.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
Key Eligibility Criteria
Disqualifiers:Aortic Regurgitation, LVEF < 20%, Others
2250 Participants Needed
Portico Valve for Aortic Stenosis
Oak Lawn, IllinoisThis trial is testing a new heart valve replacement device for patients with severe heart valve issues who are too high-risk for traditional surgery. The device is inserted through a blood vessel, making the procedure less invasive.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+
Sex:All
1242 Participants Needed
TAVR for Heart Failure
Chicago, IllinoisThe objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
178 Participants Needed
Avalus Ultra Valve for Aortic Valve Disease
Chicago, IllinoisThe purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Prosthetic Valve, Systemic Infection, Renal Failure, Pregnancy, Others
150 Participants Needed
AutoAS for Aortic Valve Stenosis
Chicago, IllinoisThis is a prospective clinical trial intended to capture echocardiographic images in patients clinically indicated for an echocardiographic examination using an additional Point of Care Ultrasound device . The images collected will be used to test and possibly validation an AI base Aortic Valve Stenosis algorithm
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Artificial Aortic Valves, Acute Cardiac Event, Others
200 Participants Needed
TAVI vs SAVR for Aortic Stenosis
Maywood, IllinoisThe purpose of the study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at intermediate surgical risk by randomizing patients to either Surgical Aortic Valve Replacement (SAVR) or TAVI with the Medtronic CoreValve® System.
Single Arm: The purpose of this trial is to evaluate the safety and effectiveness of transcatheter aortic valve implementation (TAVI) in patients with severe symptomatic Aortic Stenosis (AS) at intermediate surgical risk with TAVI. This is a non-randomized phase of the pivotal clinical trial.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
1746 Participants Needed
SAPIEN X4 THV for Failing Aortic Valves
Evanston, IllinoisThis trial tests a new artificial heart valve that can be inserted without open-heart surgery. It focuses on high-risk patients with failing aortic valves. The valve is placed using a thin tube, making the procedure safer for these patients. This new method offers a less invasive alternative to conventional surgery.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:All
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Mitral Regurgitation, Renal Insufficiency, Stroke, Others
200 Participants Needed
TAVR vs SAVR for Aortic Valve Stenosis
Maywood, IllinoisThe study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.
The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
2223 Participants Needed
ACURATE TAVR System for Aortic Stenosis
Oak Lawn, IllinoisTo evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
1948 Participants Needed
New Aortic Heart Valves for Aortic Stenosis
Oak Lawn, IllinoisThis trial is testing a new heart valve that can be inserted without open-heart surgery. It targets high-risk patients with severe aortic stenosis. The valve is put in through a small cut and helps the heart pump blood more effectively. This procedure offers an alternative to more invasive surgeries.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 100
Sex:All
333 Participants Needed
Aortic Valve Replacement for Aortic Stenosis
Evanston, IllinoisThis trial compares two methods of heart valve replacement in patients with severe narrowing of the heart valve. It aims to see if one method is better at improving blood flow and reducing symptoms without needing major surgery.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
1103 Participants Needed
J-Valve TF System for Aortic Valve Disease
Oak Lawn, IllinoisThe main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:All
Sex:All
25 Participants Needed
JenaValve Trilogy System for Aortic Regurgitation
Oak Lawn, IllinoisThis trial examines using a new heart valve replacement procedure to treat patients with severe Aortic Regurgitation. The procedure replaces the faulty heart valve to improve blood flow and reduce symptoms like fatigue and shortness of breath. The new valve is designed to be self-expanding and has a specific mechanism for secure placement.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
180 Participants Needed
PCI vs Medical Management for Aortic Stenosis
Chicago, IllinoisPatients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management.
The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance.
The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure.
The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR.
Complete Revascularization:
Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR.
Vs. Medical Therapy Alone:
No further revascularization of coronary artery lesions.
All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:All
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior CABG, Severe Mitral Regurgitation, Severe LV Dysfunction, Others
4000 Participants Needed
TAVR for Aortic Stenosis
Milwaukee, WisconsinObtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65+
Sex:All
Key Eligibility Criteria
Disqualifiers:Age < 65, LVEF ≤ 20%, Others
650 Participants Needed
Evogliptin for Aortic Stenosis
Milwaukee, WisconsinThis is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 3 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 3 arms in this study to which patients will be randomized in a ratio of 1:1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks . the 3 arms are: placebo, DA-1229 5mg GroupDA-1229 10 mg Group.
The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:35+
Sex:All
867 Participants Needed
Aortic Valve Replacement for Aortic Stenosis
Milwaukee, WisconsinTo evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
1312 Participants Needed
Edwards Bioprosthetic Heart Valves for Heart Valve Disease
Grand Rapids, MichiganThe objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
777 Participants Needed
Foldax Tria Aortic Valve Replacement for Aortic Valve Disease
Indianapolis, IndianaThis trial is testing a new artificial heart valve made from polymer material in patients who need a replacement for their damaged or malfunctioning aortic valve. The new valve helps regulate blood flow from the heart, aiming to improve heart function and patient safety. The polymeric valve has been developed to last longer and work better than current options.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
40 Participants Needed
Page 1 of 1+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Aortic Stenosis clinical trials in Chicago, IL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Aortic Stenosis clinical trials in Chicago, IL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Aortic Stenosis trials in Chicago, IL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Chicago, IL for Aortic Stenosis is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Chicago, IL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Aortic Stenosis medical study in Chicago, IL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Aortic Stenosis clinical trials in Chicago, IL ?
Most recently, we added AutoAS for Aortic Valve Stenosis, Avalus Ultra Valve for Aortic Valve Disease and SAPIEN X4 THV for Failing Aortic Valves to the Power online platform.